Cited 0 times in
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2022-09-14T01:27:33Z | - |
dc.date.available | 2022-09-14T01:27:33Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190459 | - |
dc.description.abstract | Purpose: This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and methods: We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results: The patients received anti-programmed cell death protein-1 (PD-1) (n=73, 58%), anti-programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti-PD-1/PD-L1 and anti-cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion: ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Clinical Decision-Making | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Head and Neck Neoplasms / blood | - |
dc.subject.MESH | Head and Neck Neoplasms / drug therapy* | - |
dc.subject.MESH | Head and Neck Neoplasms / mortality | - |
dc.subject.MESH | Head and Neck Neoplasms / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immune Checkpoint Inhibitors / pharmacology | - |
dc.subject.MESH | Immune Checkpoint Inhibitors / therapeutic use* | - |
dc.subject.MESH | Lymphocyte Count | - |
dc.subject.MESH | Lymphocytes | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local / blood | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy* | - |
dc.subject.MESH | Neoplasm Recurrence, Local / mortality | - |
dc.subject.MESH | Neutrophils | - |
dc.subject.MESH | Patient Selection | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment / methods | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / blood | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / drug therapy* | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / mortality | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / secondary | - |
dc.title | Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yun-Gyoo Lee | - |
dc.contributor.googleauthor | Hyun Chang | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Sang Hoon Chun | - |
dc.contributor.googleauthor | Jihyun Park | - |
dc.contributor.googleauthor | Keon Uk Park | - |
dc.contributor.googleauthor | Seong Hoon Shin | - |
dc.contributor.googleauthor | Ho Jung An | - |
dc.contributor.googleauthor | Kyoung Eun Lee | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | In Gyu Hwang | - |
dc.identifier.doi | 10.4143/crt.2020.824 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 33285051 | - |
dc.subject.keyword | Biomarkers | - |
dc.subject.keyword | Head and neck neoplasms | - |
dc.subject.keyword | Immune check point | - |
dc.subject.keyword | Platinum refractory | - |
dc.subject.keyword | Sum of target lesions | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 53 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 671 | - |
dc.citation.endPage | 677 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.53(3) : 671-677, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.